Reasons for resistance to aspirin in cardiovascular disease

Circulation. 2002 Nov 26;106(22):e181-2; author reply e181-2. doi: 10.1161/01.cir.0000037294.28723.da.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Aspirin / adverse effects
  • Aspirin / therapeutic use*
  • Blood Coagulation / drug effects
  • Blood Coagulation / genetics
  • Cardiovascular Diseases / drug therapy*
  • Cyclooxygenase Inhibitors / adverse effects
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Drug Resistance*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / drug therapy
  • Integrin beta3 / genetics
  • Platelet Activation / drug effects
  • Platelet Activation / genetics
  • Polymorphism, Genetic
  • Risk
  • Secondary Prevention
  • Treatment Failure

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Integrin beta3
  • Aspirin